Please ensure Javascript is enabled for purposes of website accessibility
Panel Endorses Widespread Use of Pfizer COVID-19 Vaccine in US
gvw_ap_news
By Associated Press
Published 4 years ago on
December 10, 2020

Share

A government advisory panel endorsed widespread use of Pfizer’s coronavirus vaccine Thursday, putting the country just one step away from launching an epic vaccination campaign against the outbreak that has killed close to 300,000 Americans.

Shots could begin within days, depending on how quickly the Food and Drug Administration signs off, as expected, on the expert committee’s recommendation.

In a 17-4 vote with one abstention, the government advisers concluded that the vaccine from Pfizer and its German partner BioNTech appears safe and effective for emergency use in adults and teenagers 16 and older.

That endorsement came despite questions about allergic reactions in two people who received the vaccine earlier this week when Britain became the first country to begin dispensing the Pfizer-BioNTech shot.

Despite all the remaining unknowns, in an emergency, “the question is whether you know enough,” said panel member Dr. Paul Offit of Children’s Hospital of Philadelphia, who concluded that the shot’s potential potential benefits outweigh its risks.

The independent review by non-government experts in vaccine development, infectious diseases and medical statistics was considered critical to boosting Americans’ confidence in the safety of the shot, which was developed at breakneck speed less than a year after the virus was identified.

The decision came as COVID-19 cases surge to ever-higher levels across the U.S., with deaths hitting an all-time, one-day high of more than 3,100 on Wednesday.

Pfizer has said it will have about 25 million doses of the two-shot vaccine for the U.S. by the end of December. But initial supplies will be limited and reserved primarily for health care workers and nursing home residents, with other vulnerable groups next in line until the shots become widely available on demand, something that will probably not happen until the spring.

The FDA Next Week Will Review a Second Vaccine

Experts estimate at least 70% of the U.S. population will have to be vaccinated to achieve herd immunity, the point at which the virus can be held in check. That means it could be several months before things start get back to normal and Americans can put away their masks.

The FDA next week will review a second vaccine, from Moderna and the National Institutes of Health, that appears about as protective as Pfizer-BioNTech’s shot. A third candidate, from Johnson & Johnson, which would require just one dose, is working its way through the pipeline. Behind that is a candidate from AstraZeneca and Oxford University

All eyes now turn to the FDA staff scientists who will make the final decision on whether to greenlight use of the Pfizer-BioNTech vaccine. Regulators not only in Britain but in Canada have already approved it for use in their countries, and President Donald Trump and White House officials have complained for weeks about the pace of FDA’s careful review.

FDA’s vaccine director Dr. Peter Marks said ahead of the expert meeting that a decision would come within “days to a week.”

“Americans want us to do a scientific review, but I think they also want us to make sure we’re not wasting time on paperwork as opposed to going forward with the decision,” FDA Commissioner Stephen Hahn said before the meeting.

A positive vote for the vaccine was virtually assured after FDA scientists issued a glowing review of the vaccine earlier in the week. Agency staffers said data from Pfizer’s ongoing study of 44,000 people showed strong protection across different age groups, races and health conditions with no major, unexpected safety problems.

It Is Not Yet Clear if It Can Stop the Silent, Symptomless Spread

The Pfizer-BioNTech shot remains experimental because that final-stage study isn’t complete. As a result, the expert panel wrestled with a list of questions that have yet to be answered.

For example, while the vaccine is more than 90% effective in blocking the symptoms of COVID-19, the FDA’s advisers stressed it is not yet clear if it can stop the silent, symptomless spread that accounts for up to half of cases.

“Even though the individual efficacy of this vaccine is very, very, very high, you really as of right now do not have any evidence” that it will lower transmission, said Dr. Patrick Moore of the University of Pittsburgh. He urged Pfizer to take additional steps to answer that question.

And the advisers are worried that Pfizer will lose its opportunity to answer critical questions as it begins offering the real vaccine to study participants who had been getting dummy shots.

The company proposed gradually moving those patients to the vaccine group, with priority based on age, health conditions and other factors. Under that plan, 70-year-old participants would cross over before healthy 30-year-olds.

Pfizer must still show whether the vaccine works in children younger than 16 and in pregnant women.

On the safety front, as widespread vaccinations begin, the first recipients will be closely tracked by government health authorities since studies in tens of thousands of people can’t detect rare risks that strike 1 in a million. Hanging over the meeting were the British allergic reactions and a warning from authorities there that people with a history of serious reactions shouldn’t get the vaccine for now.

Pfizer representatives said they have seen no signs of allergic reactions in their trial. But some of the FDA advisers fear the British warning will deter millions of Americans with allergies who might benefit from the COVID-19 vaccine from giving it a try, and urged additional studies to try to settle the issue.

“This issue is not going to die until we have better data,” Offit said.

RELATED TOPICS:

DON'T MISS

Musk PAC Tells Philadelphia Judge the $1 Million Sweepstakes Winners Are Not Chosen by Chance

DON'T MISS

Bass’ Record 61-Yard Field Goal Lifts Bills Over Dolphins in Thriller

DON'T MISS

Big Spenders: These Companies Are Giving the Most to California Legislative Candidates

DON'T MISS

Stock Market Today: Wall Street Drifts Ahead of Election Day, While Oil Rises and Yields Sink

DON'T MISS

Saints Fire Head Coach Dennis Allen After Seven-Game Losing Streak

DON'T MISS

Raiders Fire Offensive Coordinator Luke Getsy and 2 Other Offensive Coaches

DON'T MISS

Storm in the Caribbean Is on a Track to Likely Hit Cuba as a Hurricane

DON'T MISS

Israel Ends Agreement With UN Agency Providing Aid in Gaza

DON'T MISS

Demarcus Robinson’s One-Handed Catch in OT Gives Rams Win Over Seahawks

DON'T MISS

Trump, Musk and an American Masculinity Crisis

UP NEXT

Visalia Rollerblader Suffered Major Injuries After Being Struck by Vehicle

UP NEXT

Fresno County Man Indicted for Possessing Stolen Guns

UP NEXT

On Elon Musk’s X, Dems Are an Endangered Species While GOP Goes Viral

UP NEXT

New Vehicles, Face Paint and a 1,200-Foot Fall: The US Army Prepares for War With China

UP NEXT

CNN Bars Pro-Trump Guest After His ‘Beeper’ Remark to Mehdi Hasan

UP NEXT

LGBTQ Supporters Drown Out Westboro Baptists’ Anti-Gay Message in Fresno

UP NEXT

The ‘Black Insurrectionist’ Was Actually White. The Deception Did Not Stop There

UP NEXT

Washington Post Says It Will Stop Endorsing Presidential Candidates

UP NEXT

What Happened When a Barber Told Trump About His $15,000 Electric Bill

UP NEXT

Los Angeles Times Editorials Editor Resigns After Newspaper Withholds Presidential Endorsement

Stock Market Today: Wall Street Drifts Ahead of Election Day, While Oil Rises and Yields Sink

29 mins ago

Saints Fire Head Coach Dennis Allen After Seven-Game Losing Streak

33 mins ago

Raiders Fire Offensive Coordinator Luke Getsy and 2 Other Offensive Coaches

37 mins ago

Storm in the Caribbean Is on a Track to Likely Hit Cuba as a Hurricane

40 mins ago

Israel Ends Agreement With UN Agency Providing Aid in Gaza

45 mins ago

Demarcus Robinson’s One-Handed Catch in OT Gives Rams Win Over Seahawks

1 hour ago

Trump, Musk and an American Masculinity Crisis

1 hour ago

What One Tossup District Says About the Trump-Harris Battle for the Suburbs

1 hour ago

Herbert Shines, Chargers Defense Dominates in Win Over Browns

1 hour ago

US Confirms Reports That Iran Arrested an Iranian-American Citizen

2 hours ago

Musk PAC Tells Philadelphia Judge the $1 Million Sweepstakes Winners Are Not Chosen by Chance

PHILADELPHIA — A lawyer for Elon Musk’s political action committee told a judge in Philadelphia on Monday that so-called “winner...

9 mins ago

9 mins ago

Musk PAC Tells Philadelphia Judge the $1 Million Sweepstakes Winners Are Not Chosen by Chance

15 mins ago

Bass’ Record 61-Yard Field Goal Lifts Bills Over Dolphins in Thriller

29 mins ago

Big Spenders: These Companies Are Giving the Most to California Legislative Candidates

29 mins ago

Stock Market Today: Wall Street Drifts Ahead of Election Day, While Oil Rises and Yields Sink

33 mins ago

Saints Fire Head Coach Dennis Allen After Seven-Game Losing Streak

Raiders
37 mins ago

Raiders Fire Offensive Coordinator Luke Getsy and 2 Other Offensive Coaches

40 mins ago

Storm in the Caribbean Is on a Track to Likely Hit Cuba as a Hurricane

45 mins ago

Israel Ends Agreement With UN Agency Providing Aid in Gaza

Search

Send this to a friend